mouse igg2b  (InvivoGen)

Journal: bioRxiv

Article Title: Acute degron-mediated RUNX1 loss reprograms enhancer activity to epigenetically drive epithelial destabilization and initiate cancer hallmarks

doi: 10.64898/2026.03.26.711344

Figure Lengend Snippet: A) Chromosomal tracks depicting RUNX1 binding, chromatin contacts, ATAC and H3K27ac signals at chr15-101Mb region encompassing the ALDH1A3 locus that is upregulated upon the loss of RUNX1. B) Flow cytometry histograms of ALDH activity measured by an ALDEred assay at different timepoints following RUNX1 ablation. C) Quantification of ALDH high cells above DEAB-ALDH inhibitory controls indicate the percentage of cells that are ALDH bright in the DMSO baseline versus dTAGV1 treatment. D) Flow cytometry histograms of CD24 staining at different timepoints following RUNX1 ablation. E) Quantification of CD24+ cells above isotype controls indicates the percentage of CD24 high non-BCSCs in DMSO versus dTAGV1 treatment. F) MCF10A-R1F cells initially treated for 24hrs with DMSO or dTAGV1 were then subsequently placed in an anchorage-independent condition demonstrating an increased number of viable cells upon RUNX1 ablation. G) Relative MTS absorbance (450nm) as a measure of cell metabolism/ viability. Values are expressed as a percentage of vehicle control absorbance at multiple 4-hydroxycyclophosphamide (4-HC) dosages at 48hrs.

Article Snippet: Cells were stained with CD24 (Miltenyi Biotec, 130-108-352) or isotype (Miltenyi Biotec, 130-124-062) antibodies at the manufacturer’s suggested concentration for 20 minutes at 4°C, washed and acquired using a MACSquant YVB.

Techniques: Binding Assay, Flow Cytometry, Activity Assay, Staining, Control